ArriVent BioPharma, Inc. (NASDAQ:AVBP – Get Free Report) has earned an average recommendation of “Moderate Buy” from the nine brokerages that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, six have assigned a buy recommendation and one has issued a strong buy recommendation on the company. Get ArriVent BioPharma alerts:View Our Latest Stock Analysis on AVBPHedge Funds Weigh In On ArriVent BioPharmaArriVent BioPharma Stock Down 0.5%Institutional investors and hedge funds have recently modified their holdings of the business. Sell-side analysts anticipate that ArriVent BioPharma will post -3.9 earnings per share for the current fiscal year. Featured StoriesReceive News & Ratings for ArriVent BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArriVent BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.